In particular, a better understanding of modulation of PSA expression and PSMA expression by innovative therapeutics active in prostate cancer patients resistant to hormone deprivation, such as abiraterone and 2-(7-Methyl-11-indol-3-yl)quinoline (VPC-13566), would greatly support therapy planning and monitoring under these conditions. This evidence concerns the gene FOLH1 and Familial prostate cancer.